Our research focuses on understanding the molecular basis of autoimmune conditions in haematology, particularly immune thrombocytopenia (ITP), a condition leading to premature destruction of platelets.
We combine genetic and genomic analysis of individuals with extreme phenotypes, CRISPR-based in vitro functional validation, and parallel ‘omic' approaches to define novel pathways regulating autoimmunity (eg Afzaku B et al Nat Immunol 2017 18:813-823).
et al., 2022, Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia, New England Journal of Medicine, Vol:386, ISSN:0028-4793, Pages:1421-1431
et al., 2022, A Single-Arm, Long-Term Efficacy and Safety Study of Subcutaneous Romiplostim in Children with Immune Thrombocytopenia., Blood Adv
et al., 2022, Whole genome sequences discriminate hereditary hemorrhagic telangiectasia phenotypes by non-HHT deleterious DNA variants, Blood Advances, ISSN:2473-9529
et al., 2021, Autocrine vitamin D signaling switches off pro-inflammatory programs of T(H)1 cells, Nature Immunology, Vol:23, ISSN:1529-2908, Pages:62-+
et al., 2021, Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets, Blood, Vol:138, ISSN:0006-4971, Pages:1481-1489